MKM. V. Krasilnikova

M. V. Krasilnikova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


M. V. Krasilnikova has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Svetlana Mann

    Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Ministry of Healthcare, Samora Machel Street, 1, GSP-7, Moscow 117198, Russia

    4 shared publications
  • Evgeny Litvin

    Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

    3 shared publications
  • N. A. Karamjan

    Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

    3 shared publications
  • M. E. Lokhmatova

    Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

    2 shared publications
  • Natalia Karamyan

    Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

    2 shared publications
  • Svetlana Plyasunova

    The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

    2 shared publications

Latest Publications

  • Russia’s first identified case of abnormal Hemoglobin Kansas with low oxygen affinity, a rare cause of cyanosis

    by Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology, M.V. Krasilnikova, N.A. Karamyan, S.G. Mann, V.A. Voropayeva, Ye.A. Litvin

    Diagnosis of rare causes of cyanosis is if a certain difficulty. A clinical case report of cyanosis caused by the presence of abnormal Hemoglobin (Hb) Kansas with reduced oxygen affinity is presented. This is the Russia’s first detected and recorded case in a Russian child with cyanosis and mild anemia. As a result of routine examination using capillary electrophoresis and high-performance liquid chromatography, a pathological fraction of Hb was detected. Molecular genetic research according to Sanger determined a mutation in codon 102 of the β-globin gene with the replacement of aspartic acid with threonine, corresponding to rare abnormal Hb Kansas with reduced oxygen affinity.

  • Open Access

    Rare unstable hemoglobin Hakkari in Russia: a case report and literature review

    by S. G. Mann, М. В. Красильникова, N. A. Karamjan, M. E. Lokhmatova, A. O. Koposova, E. A. Litvin, S. A. Plyasunova

    Here we report the first case of unstable hemoglobin Hakkari identified in Russia to our knowledge. It was diagnosed in a two-year-old Russian boy with severe transfusion-dependent anemia caused by a de novo mutation in the b-globin gene [b31(B13) Leu→Arg, HBB: c.95TG]. Routine diagnostic methods were not effective, and his diagnosis was not established until gene sequencing of the globin gene was performed. A comparative analysis of all known cases of unstable Hb Hakkari allows for the identification of similarities and differences in the clinical and laboratory course of the disease. The patient's parents gave their consent to the use of their child's data, including photographs, for research purposes and in publications.


  • Open Access

    Unstable abnormal hemoglobins found in Russia in the past 10 years

    by M. E. Lokhmatova, N. E. Sokolova, М. В. Красильникова, E. A. Litvin, N. A. Karamjan, S. G. Mann, S. A. Plyasunova, N. S. Smetanina

    From 2010 to 2020, we investigated 197 children with hemolytic anemia of unknown etiology at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. Fifty-four of them were found to have hemoglobinopathy caused by unstable abnormal hemoglobins: Hb Monroe/Kairouan, Hb Tacoma, Hb Köln/SanFrancisco, Hb Cheverly, Hb City of Hope, Hb Southampton/Casper, Hb M-Hyde Park/Akita/Milwaukee-2, Hb Buenos Aires/Bryn Mawr, Hb Louisville/Bucureşti, Hb Genova/Hyogo, Hb Roseau-Pointe a Pitre, Hb Bristol/Alesha, Hb Henri Mondor, Hb Knossos, Hb Leiden, Hb Little Venice, Hb Olmsted, Hb Sabine, Hb Showa-Yakushiji, Hb Terre Haute, Hb Tübingen, Hb Quin-Hai. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. The patients' parents signed the informed consent for molecular genetic testing and gave their consent to the use of their children's data, including photographs, for research purposes and in publications.

  • Open Access

    First cases of Hb Lepore in the Russian Federation

    by М. В. Красильникова, N. A. Karamyan, E. A. Litvin, S. G. Mann

    Hb Lepore, as the result of fusion of the b- and d-globin genes, leads to decreased amount of non-a-globin chains availability for hemoglobin formation. Hb Lepore, up to now, was not identified among Russian patients. We provide clinical and laboratory information on Hb Lepore Boston–Washington in two cases, one of them familial. A small amount of abnormal Hb was detected by capillary electrophoresis, an abnormal globin chain was shown by HPLC, and the final diagnosis of Hb Lepore Boston– Washington was made by molecular biological analysis of globin genes. Peripheral blood for all affected people revealed RBC’s hypochromia microcytosis and normal Hb concentration. The parents of the patients agreed to use the information, including photos of children, in scientific research and publications.

  • Open Access

    Alternative therapies of manifest forms of β-thalassemia: stimulation of fetal hemoglobin synthesis

    by M. V. Krasilnikova, N. A. Karamjan

    An imbalance in the synthesis and ratio of α and non-α globin chains is the major pathophysiological mechanism leading toineffective erythropoiesis and hemolysis in severe form of the β-thalassemia. Phenotype in patients who retain the capacity tosynthesize fetal hemoglobin (HbF) is milder due to decreasing α- /non-α globin chain imbalance. Induction of HbF might be aneffective therapeutic strategy for severe form of β-thalassemia. This literature review presents data about efficiency safenessof different medication and their combination, which stimulate synthesis of HbF. This review can provide a new insight into thecurrent status and future perspectives in HbF reactivation as treatment option for severe form of β-thalassemia.